Our Founder Tadeusz Hawrot speaks about the “Future of Psychedelic Medicine in the EU”, alongside Cyrus Engerer, MEP for Malta and Mikuláš Peksa, MEP for Czechia, with Steph Price moderating the PSYCH Symposium on 6th July in London, at the British Museum.

Open Access Government publishes an article by Tadeusz Hawrot, Founder of PAREA, on the potential of psychedelic therapies in transforming EU's mental health care approach. A timely piece on the underserved area of psychedelic therapies. Read the full article here.

The BBC covers a historic moment in medicine. Starting today, Australia is the first country to classify psychedelics as medicines at a national level. Additionally, the Royal Australian and New Zealand College of Psychiatrists has just issued a relevant memorandum on the therapeutic use of these substances. PAREA founder, Tadeusz Hawrot, speaks with Polish television TVP World about concerns & progressions moving forward.

Our latest news release is out, covering key relevant advancements in the field of psychedelics. For the 1st time the UN and EMCDDA included chapters on psychedelics in their reports. The FDA in the US issued its guidelines. Nature paper explores the potential of psychedelics in brain development.

In lead-up to the PSYCH Symposium, July 6th at the British Museum, Psychedelic Health interviews panel members Tadeusz Hawrot, founder of PAREA, and MEP for Czechia, Mikuláš Peksa about their thoughts on the future of Psychedelic Medicine in the European Union. Read about their thoughts, including parallels between psychedelics and stroke care in the interview here.

The largest gathering of its kind, MAPS Psychedelic Science took place in Denver, Colorado bringing 11,000 attendees together with experts and innnovators to converge and share. PAREA founder, Tadeusz Hawrot, spoke during the policy session "From research to regulatory changes: Australia, the EU, and beyond" on Thursday.

Voices from the front lines, founder of PsyPAN, Psychedelic Participant Action Network, Ian Rollier is interviewed by EURACTIVE on the transformative process of the innovative mental health treatments, therapeutic value and the effects of psilocybin on depression.

In solidarity, the EU Commission moves to support its citizens and their mental health and has released a comprehensive outline featuring 20 initiatives aimed at destigmatizing mental health issues and guaranteeing universal care access. €1.23 billion has been designated for this initiative. The new measures aim to improve prevention, treatment and care, plus social reintegration after recovery, truly making mental health a priority.

PAREA's latest EU Insights edition delves into the crucial intersection of EU policy and psychedelic science, particularly focusing on the recent transformation of EU pharma legislation. This update also introduces our new feature - a curated selection of the top psychedelic science developments. Support our mission to enjoy exclusive benefits and contribute to this ground-breaking field.

We are pleased to share a video message from the PAREA Founder marking the launch of the MEP Action Group for the Medical Use of Psychedelics in the European Parliament:

We are thrilled to announce the launch of the Members of the European Parliament Action Group for the Medical Use of Psychedelics (MEP AG), a platform to promote collective action for safe, responsible, and effective psychedelic treatments. The MEP AG, comprised of MEPs from seven EU nations, will be an important vehicle for change. PAREA, along with PsychedelicsEUROPE, provides secretariat support for the Group.

As a cosignatory of the EU Mental Health in all Policies Thematic Network Joint Statement, led by the Mental Health Europe, PAREA supports the crucial importance of prioritizing mental health in all policies across Europe. Recognizing the societal and economic benefits, we urge policymakers to adopt a comprehensive, multi-sectoral approach that promotes mental health and reduces inequalities.

Join our Founder at the PSYCH Symposium in London this July 6th, where he will be speaking about the future of psychedelic medicine in Europe. Taking place at the historic British Museum, he will be discussing this emerging industry alongside around 350+ business leaders, key innovators & policymakers.

Use our personal discount code for 15% off your ticket. Secure your seat now.

The European Commission has published a revision of pharmaceutical legislation, marking the most significant reform of the bloc's pharma rules in 20 years. This comprehensive overhaul is set to make a substantial impact in Europe and globally. PAREA has actively contributed input leading up to its publication and remains engaged in shaping the legislation during the institutional negotiations phase.

On 24th April, our Founder participated in the EC DG SANTE’s stakeholder event – “A comprehensive approach to mental health” and pitched for an EU-level coordination action to help member states prepare for the roll-out of psychedelic medicines. On this occasion, PAREA submitted concrete ideas on how to make this happen that you can access here.

We have just released the 3rd edition of EU Insights which can be browsed here. This newsletter will be freely available and you can subscribe at the bottom of our website. You can also help support our mission by becoming a funding supporter.

PAREA makes a submission to the EC consultations Stakeholders' Targeted Consultation on EU4Health: future priorities, orientation and needs’. The consultation results will be used in the consultation report and will also feed into the EU4Health stakeholders’ conference on 9 June 2023.

PAREA’s Tadeusz Hawrot discusses the organisation’s recent meeting with the European Commission’s Health Directorate (DG SANTE), and the need to begin work on equitable access to psychedelic therapies in Europe in the Psychedelic Health article: Building for the future: Preparing for equitable access to psychedelic medicines in the EU.

PAREA Chair Prof. David Nutt writes in Open Access Government “Why Europe needs to catch up with psychedelic research”. See page pages 1, 2 and the full issue here.

In early April, PAREA met with Stefan Schreck, Advisor for Stakeholder Relations at the European Commission DG SANTE (health directorate). Among discussed topics, PAREA emphasized a need for the EU Member States to proactively prepare for the roll-out of psychedelic medicines in order to build the necessary expertise and infrastructure for the highest quality, safe, affordable, and equitable access to psychedelic medicines.